Reviva Pharmaceuticals Secures $3.33 Price Target Amid Analyst Ratings

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have garnered a consensus rating of “Moderate Buy” from eight research firms following recent evaluations. According to data from MarketBeat, one analyst has issued a sell recommendation while seven analysts recommend buying the stock. The average price target over the next twelve months is set at $3.33.

Analysts have provided varied insights into Reviva Pharmaceuticals. On December 23, 2023, HC Wainwright reaffirmed a “buy” rating and established a target price of $4.00. In contrast, Wall Street Zen upgraded Reviva from a “sell” to a “hold” rating on December 27, 2023. Meanwhile, Weiss Ratings maintained a “sell (e+)” rating on October 8, 2023, reflecting some caution among investors.

Additional recommendations include a “buy” rating from D. Boral Capital, which also set a target price of $2.00 on December 23, 2023, and a similar endorsement from Chardan Capital on January 5, 2024.

Recent Earnings and Market Activity

Reviva Pharmaceuticals recently reported its quarterly earnings on November 13, 2023. The company posted an earnings per share (EPS) of ($0.06), surpassing the consensus estimate of ($0.11) by $0.05. Analysts expect Reviva to report an EPS of (0.97) for the current fiscal year.

Institutional trading activity has been notable as various hedge funds have adjusted their holdings in Reviva. Armistice Capital LLC acquired a new position in the second quarter, valued at approximately $1,026,000. Similarly, 683 Capital Management LLC added shares worth $381,000 during the same period. Persistent Asset Partners Ltd increased its stake by 300%, now owning 641,174 shares valued at $244,000 after purchasing an additional 480,864 shares.

Furthermore, Millennium Management LLC raised its holdings by 15%, bringing its total to 1,711,221 shares valued at $631,000. Overall, approximately 63.18% of Reviva’s stock is held by institutional investors.

Company Overview

Founded in 2002 and headquartered in Coral Gables, Florida, Reviva Pharmaceuticals is a specialty pharmaceutical company dedicated to the acquisition, development, and commercialization of prescription drug products within the United States and select international markets. The company targets under-promoted, off-patent pharmaceuticals, aiming to enhance patient compliance and therapeutic outcomes through innovative dosage forms.

Reviva’s core activities include identifying FDA-approved drug candidates and developing formulations that cater to niche or underserved patient populations, including pediatric and orphan indications. The company actively supports regulatory filings to advance its product offerings.

For those interested in staying updated on Reviva Pharmaceuticals, MarketBeat offers a daily newsletter summarizing the latest news and analyst ratings.